US FDA accepts Somaxon's complete response for Silenor
This article was originally published in Scrip
The US FDA has accepted Somaxon's resubmission of the NDA for its troubled insomnia drug Silenor (doxepin) following the complete response letter it issued in June. The company's share price soared by 82%, closing at $2.40 on Nasdaq on January 22nd.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.